Pediatric MS patients with a primary progressive-like disease may still have relevant inflammatory activity and may benefit from regular MS treatment

Mult Scler. 2020 Dec;26(14):1962-1964. doi: 10.1177/1352458520921367. Epub 2020 May 14.

Authors

Arlette L Bruijstens¹, Katelijn M Blok¹, Joost Smolders^{1

2}, Beatrijs Ha Wokke¹, Rinze F Neuteboom¹

Affiliations

¹ Department of Neurology, Erasmus University Medical Center, Rotterdam, The Netherlands.
² Neuroimmunology Research Group, Netherlands Institute for Neuroscience, Amsterdam, The Netherlands.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Adolescent
Child
Disease Progression
Humans
Multiple Sclerosis* / drug therapy
Multiple Sclerosis, Chronic Progressive* / drug therapy